The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management.

Competing Interests: Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-2843/coif). MHD has received grants from AstraZeneca. CH has received honoraria paid to self from Abbvie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, Roche, Takeda and has research grants paid to institution from AstraZeneca, EMD Serono and Roche. The authors have no other conflicts of interest to declare.